References
- Kasama T, Shiozawa F, Isozaki T, et al. Effect of the H2 receptor antagonist nizatidine on xerostomia in patients with primary Sjogren's syndrome. Mod Rheumatol. 2008;18:455–9.
- Nakayamada S, Saito K, Umehara H, et al. Efficacy and safety of mizoribine for the treatment of Sjogren's syndrome: a multicenter open-label clinical trial. Mod Rheumatol. 2007;17:464–9.
- Kohashi M, Ishimaru N, Arakaki R, Hayashi Y. Effective treatment with oral administration of rebamipide in a mouse model of Sjogren's syndrome. Arthritis Rheum. 2008;58:389–400.
- Alpoz E, Guneri P, Onder G, Cankaya H, Kabasakal Y, Kose T. The efficacy of Xialine in patients with Sjogren's syndrome: a single-blind, cross-over study. Clin Oral Investig. 2008;12:165–72.
- Willeke P, Schluter B, Becker H, Schotte H, Domschke W, Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjogren syndrome: a pilot trial. Arthritis Res Ther. 2007;9:R115.
- Pinheiro MN Jr, dos Santos PM, dos Santos RC, Banos Jde N, Passos LF, Cardoso Neto J. Oral flaxseed oil (Linum usitatissimum) in the treatment for dry-eye Sjogren's syndrome patients. Arq Bras Oftalmol. 2007;70:649–55.
- Delaleu N, Madureira AC, Immervoll H, Jonsson R. Inhibition of experimental Sjogren's syndrome through immunization with HSP60 and its peptide amino acids 437-460. Arthritis Rheum. 2008;58:2318–28.
- Zhang ZY, Li RB, Jiang Y, et al. High-dose immunosuppression and autologous peripheral blood stem cell transplantation for immunological reconstitution in two patients with primary Sjogren's syndrome. Zhonghua Nei Ke Za Zhi. 2007;46:926–9.